News
AMLX
5.02
-11.62%
-0.66
Weekly Report: what happened at AMLX last week (1104-1108)?
Weekly Report · 3d ago
Cautious Hold on Amylyx Pharmaceuticals Amid Uncertainty in Pipeline Progress
TipRanks · 3d ago
Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
Amylyx Pharmaceuticals Price Target Raised to $12.00/Share From $8.00 by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Maintains Buy on Amylyx Pharma, Raises Price Target to $12
Benzinga · 6d ago
Amylyx price target raised to $12 from $8 at H.C. Wainwright
TipRanks · 6d ago
AMYLYX PHARMACEUTICALS, INC. <AMLX.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $12 FROM $8
Reuters · 6d ago
U.S. RESEARCH ROUNDUP-Bath & Body Works, Datadog, Savers Value Village
Reuters · 6d ago
Amylyx Pharmaceuticals Q3 2024 Financial Highlights
TipRanks · 6d ago
AMYLYX PHARMACEUTICALS, INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024
Press release · 11/07 21:43
Amylyx Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/07 17:20
BRIEF-Amylyx Pharmaceuticals Reports Q3 2024 Financial Results
Reuters · 11/07 12:50
Amylyx reports Q3 EPS ($1.07), consensus (71c)
TipRanks · 11/07 12:42
Amylyx Pharma Q3 2024 Adj. EPS $(0.53) Beats $(0.71) Estimate, Sales $416.000K Down From $102.693M YoY
Benzinga · 11/07 12:41
AMYLYX PHARMACEUTICALS INC: CASH RUNWAY EXPECTED INTO 2026
Reuters · 11/07 12:00
Press Release: Amylyx Pharmaceuticals Reports -2-
Dow Jones · 11/07 12:00
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Simply Wall St · 11/04 19:02
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Seeking Alpha · 11/04 15:32
Press Release: Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Dow Jones · 11/04 14:04
Weekly Report: what happened at AMLX last week (1028-1101)?
Weekly Report · 11/04 09:24
More
Webull provides a variety of real-time AMLX stock news. You can receive the latest news about Amylyx Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.